Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement

NEXT STORY
Exagen Featured in Nine Scientific Presentations at 2019 ACR/ARHP Annual Meeting in Atlanta
PREV STORY
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

author_avatar
NASDAQ Market News

Inventiva Reports First-Half of 2021 Financial Information

author_avatar
NASDAQ Market News

Interpace Diagnostics Group Reports First Quarter 2018 Financial Results, Business Progress and Recent Accomplishments

Revenue Grew 39% Over the Prior Year’s Quarter and 10% Over the Prior Period ...

author_avatar
NASDAQ Market News